Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups race to turn algorithmic magic into actual treatments. “We’ll hopefully have some AI-designed drugs in clinical trials by the end of the year,” the firm’s Nobel Prize-winning CEO Demis Hassabis told a panel at the World Economic Forum in Davos this week. “That’s the plan.” The potential of AI-powered drug discovery is huge. Instead of spending years or even decades testing chemicals by hand, machine learning algorithms can sift through mountains of data to spot patterns and predict which molecules could…
This story continues at The Next Web